Why is Novartis India Ltd falling/rising?

Short-Term Price Movement and Market Outperformance

Novartis India Ltd has demonstrated robust gains in the recent trading sessions, with the stock appreciating by 5.68% over the past week and 6.16% in the last month. Year-to-date, the stock has risen by 6.21%, contrasting favourably against the Sensex, which declined by 1.65% over the same period. This outperformance is further underscored by the stock’s consecutive two-day gain, delivering an 8.19% return in that span. On 04-Feb, the stock reached an intraday high of ₹841.65, marking an 8.26% increase from previous levels and outperforming its sector by 6.62% on the day.

Technical indicators also support this upward trend, with the current price sitting above the 5-day, 20-day, and 50-day moving averages, signalling positive short-term momentum. However, it remains below the 100-day and 200-day moving averages, suggesting some caution in the medium to long term.

Fundamental Strengths Supporting the Rally

Novartis India’s financial fundamentals provide some rationale for the recent price appreciation. The company maintains a zero debt-to-equity ratio, indicating a strong balance sheet with no leverage risk. Operating profit has exhibited healthy long-term growth, expanding at an annualised rate of 57.68%, which is a positive signal for investors seeking sustainable earnings growth.

Return on equity (ROE) stands at a respectable 12.5%, and the stock trades at a price-to-book value of 2.6, suggesting a fair valuation relative to its peers. Despite the stock’s negative return of 2.95% over the past year, profits have increased by 12.7%, reflecting operational resilience. The company’s PEG ratio of 1.7 indicates that the stock’s price growth is somewhat aligned with its earnings growth, which may appeal to value-conscious investors. Additionally, the stock offers a high dividend yield of 3.22%, enhancing its attractiveness for income-focused portfolios.

Challenges Tempering Investor Enthusiasm

Despite these positives, there are notable concerns that temper the bullish sentiment. The company reported disappointing quarterly results for the period ending 25 Dec, with profit after tax (PAT) falling sharply by 36.8% to ₹16.09 crores. Net sales also declined by 7.63% to ₹85.90 crores, signalling potential headwinds in revenue generation. Furthermore, the debtors turnover ratio for the half-year stood at a low 7.28 times, indicating slower collection efficiency which could impact cash flows.

Investor participation appears to be waning, with delivery volumes falling by 7.65% compared to the five-day average, suggesting reduced conviction among shareholders. Domestic mutual funds hold a negligible stake of just 0.01%, which may reflect a cautious stance by institutional investors who typically conduct thorough due diligence. This limited institutional interest could be a factor restraining more sustained price gains.

Moreover, the stock has underperformed broader benchmarks such as the BSE500 over the last three years, one year, and three months, highlighting challenges in delivering consistent long-term returns despite recent short-term rallies.

Balancing Short-Term Gains with Long-Term Risks

The recent surge in Novartis India’s share price appears to be driven primarily by short-term market dynamics and technical momentum rather than a fundamental turnaround. While the company’s strong operating profit growth and solid balance sheet provide a foundation for optimism, the negative quarterly earnings and subdued institutional interest raise questions about the sustainability of the rally.

Investors should weigh the stock’s attractive dividend yield and fair valuation against the risks posed by declining sales and profit margins. The stock’s outperformance relative to the Sensex and sector in the near term is encouraging, but the underwhelming long-term returns and recent financial setbacks suggest caution.

In conclusion, Novartis India Ltd’s price rise on 04-Feb reflects a complex interplay of positive technical signals and underlying fundamental challenges. Market participants may view the stock as an opportunity for tactical gains, but a comprehensive assessment of its financial health and competitive positioning remains essential for longer-term investment decisions.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →